Latest Articles about RGLS

Isis Misses on Both Counts - Analyst Blog

Zacks Equity Research — Wed, 07 Nov 2012 20:35:01 Z

Isis Pharmaceuticals Inc. ( ISIS ) reported a adjusted net loss of 33 cents per share in the third quarter of 2012, wider than the year-ago loss of 27 cents and the Zacks Consensus Estimate

Active week for IPOs marred by lackluster trading

Renaissance Capital — Sat, 06 Oct 2012 01:47:12 Z

The fourth quarter got off to an active start this week as six of seven deals on the calendar priced. The trend of pricing pressure continued in October’s first week as four of

Six More IPOs this Week

chris.preston@wyattresearch.com (Chris Preston) — Sat, 06 Oct 2012 01:11:59 Z

The IPO market heated up in September. October is off to an even faster start. Six companies held IPOs this week. While none of them were household names, the sheer quantity speaks to the

Regulus Therapeutics prices IPO at $4.00 as expected

Renaissance Capital — Thu, 04 Oct 2012 21:04:42 Z

Regulus Therapeutics, an early stage biotech developing microRNAs treatments for multiple serious diseases, raised $45 million by offering 11.3 million shares at $4 per share. The company,